teva

Teva Releases Q1 2025 Aide MemoireTeva Releases Q1 2025 Aide Memoire

Teva Releases Q1 2025 Aide Memoire

March 27, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) --…

1 month ago
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

March 27, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) --…

1 month ago
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns DiseaseTeva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET February 22, 2025 02:20 ET  | Source: Teva…

2 months ago
Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S.Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®…

2 months ago
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)

February 18, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) --…

2 months ago
Teva to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceTeva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 23, 2024 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) --…

4 months ago
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in JapanTeva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

December 05, 2024 18:00 ET | Source: Teva Pharmaceutical Industries Ltd Teva entered into an agreement with JKI Co., Ltd.…

5 months ago
Teva to Present at the Jefferies London Healthcare ConferenceTeva to Present at the Jefferies London Healthcare Conference

Teva to Present at the Jefferies London Healthcare Conference

November 08, 2024 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) --…

6 months ago